v3.26.1
Stock-Based Compensation - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 22, 2026
USD ($)
Holder
shares
Jan. 01, 2026
shares
Mar. 31, 2024
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Dec. 31, 2025
shares
Aug. 31, 2024
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Common stock reserved for future issuance | shares       9,162,000   9,162,000   7,885,000  
Options to purchase shares of common stock | shares       5,945,000   5,945,000   4,234,000  
Stock-based compensation expense | $       $ 3,222,000 $ 1,693,000 $ 4,593,000 $ 3,490,000    
Expected term       5 years 3 months 18 days 5 years 10 months 24 days 5 years 10 months 24 days 5 years 10 months 24 days    
Expected volatility       105.00% 105.00% 107.00% 105.00%    
Risk-free interest rate       4.20% 4.00% 4.00% 4.40%    
Total intrinsic value of stock options exercised | $           $ 14,000 $ 0    
Unrecognized compensation cost | $       $ 0   $ 0      
Weighted-average grant date per share fair value of options granted | $ / shares       $ 1.12 $ 0.89 $ 1.05 $ 1.89    
2024 Incentive Award Plan                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Term of the plan     10 years            
Number of shares authorized for issuance | shares       5,068,078   5,068,078      
Aggregate number of shares issued increased | shares   1,120,362              
Number of shares remained available for grant | shares       2,724,148   2,724,148      
ESPP                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Common stock reserved for future issuance | shares       492,641   492,641      
Shares issued under ESPP | shares           34,610 85,568    
Unrecognized compensation cost | $       $ 300,000   $ 300,000      
Repriced Options                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Options to purchase shares of common stock | shares       2,208,476   2,208,476      
Merger Agreement | Serapha Bio, Inc. | Options to Purchase Common Stock                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Plan modification, number of accelerated vesting options to purchase shares of common shares | shares 5,945,008                
Plan modification, number of option holders affected | Holder 48                
Stock-based compensation expense | $       $ 2,000,000   $ 2,000,000      
Incremental compensation cost resulting from extension of exercise period and acceleration of premium end date | $ $ 400,000                
Expected term 9 months 18 days                
Expected volatility 98.80%                
Risk-free interest rate 4.00%                
Expected dividend yield 0.00%                
Maximum | Repriced Options                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Options to purchase shares of common stock | shares                 3,484,346
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Stock-based compensation expense | $       2,296,000 $ 1,051,000 3,276,000 $ 2,133,000    
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Merger Agreement | Serapha Bio, Inc. | Options to Purchase Common Stock                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Stock-based compensation expense | $       1,500,000   1,500,000      
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Stock-based compensation expense | $       926,000 $ 642,000 1,317,000 $ 1,357,000    
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Merger Agreement | Serapha Bio, Inc. | Options to Purchase Common Stock                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Stock-based compensation expense | $       $ 500,000   $ 500,000